Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) – Investment analysts at B. Riley issued their Q2 2022 earnings estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Tuesday, June 14th. B. Riley analyst M. Mamtani anticipates that the company will earn ($0.03) per share for the quarter. B. Riley currently has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.17) per share. B. Riley also issued estimates for Lineage Cell Therapeutics’ Q3 2022 earnings at ($0.04) EPS, Q4 2022 earnings at ($0.04) EPS, FY2022 earnings at ($0.15) EPS, FY2023 earnings at ($0.14) EPS and FY2024 earnings at ($0.07) EPS.
A number of other equities analysts have also recently issued reports on LCTX. Maxim Group reiterated a “buy” rating and set a $5.00 target price on shares of Lineage Cell Therapeutics in a report on Friday, May 13th. TheStreet cut Lineage Cell Therapeutics from a “c-” rating to a “d+” rating in a report on Thursday, February 24th. Dawson James reiterated a “buy” rating and set a $6.00 target price on shares of Lineage Cell Therapeutics in a report on Friday, March 11th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Lineage Cell Therapeutics in a research note on Friday, March 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $6.00.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.05). The firm had revenue of $5.24 million for the quarter, compared to the consensus estimate of $12.07 million. Lineage Cell Therapeutics had a negative return on equity of 27.43% and a negative net margin of 528.23%.
Large investors have recently made changes to their positions in the stock. Morgan Stanley lifted its holdings in Lineage Cell Therapeutics by 16.5% in the second quarter. Morgan Stanley now owns 128,762 shares of the company’s stock valued at $367,000 after buying an additional 18,235 shares during the period. Royal Bank of Canada boosted its position in Lineage Cell Therapeutics by 97.0% during the 2nd quarter. Royal Bank of Canada now owns 9,088 shares of the company’s stock valued at $26,000 after buying an additional 4,475 shares during the period. Invesco Ltd. purchased a new stake in shares of Lineage Cell Therapeutics in the 2nd quarter worth about $126,000. Citigroup Inc. lifted its position in Lineage Cell Therapeutics by 1,082.0% during the 3rd quarter. Citigroup Inc. now owns 137,858 shares of the company’s stock valued at $347,000 after acquiring an additional 126,195 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Lineage Cell Therapeutics by 625.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 97,071 shares of the company’s stock valued at $245,000 after acquiring an additional 83,697 shares during the period. 45.12% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Dipti Amin bought 35,000 shares of the business’s stock in a transaction that occurred on Monday, March 28th. The stock was acquired at an average cost of $1.63 per share, for a total transaction of $57,050.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders purchased a total of 53,650 shares of company stock valued at $83,887 over the last quarter. 26.20% of the stock is currently owned by company insiders.
About Lineage Cell Therapeutics (Get Rating)
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Lineage Cell Therapeutics (LCTX)
- Wix.com Stock Nearing a Bottom Wick
- Home Depot May Have Value In The Long Term:
- A Game-Changing Deal For Blink Charging
- The Insiders Are Selling Chevron But You Shouldn’t
- Two Retailers The Analysts Are Buying
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.